Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Preparation of 1° Amines: Gabriel Synthesis01:28

Preparation of 1° Amines: Gabriel Synthesis

4.7K
Direct alkylation is not a suitable method for synthesizing amines because it produces polyalkylated products. Gabriel synthesis is the most preferred method to exclusively make primary amines. The method uses phthalimide, which contains a protected form of nitrogen that participates in alkylation only once to predominantly give primary amines.
Strong bases like NaOH or KOH deprotonate the phthalimide to form the corresponding anion, which acts as a nucleophile. Further, the anion attacks an...
4.7K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

1.0K
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.0K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.7K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.7K
Preparation of 1° Amines: Azide Synthesis01:22

Preparation of 1° Amines: Azide Synthesis

4.7K
Direct alkylation of ammonia produces polyalkylated amines, along with a quaternary ammonium salt. To exclusively prepare primary amines, the azide synthesis method can be used.
Azide ions act as good nucleophiles and react with unhindered alkyl halides to form alkyl azides. Alkyl azides do not participate in further nucleophilic substitution reactions, thereby eliminating the chances of polyalkylated products. Alkyl azides are reduced by hydride-based reducing agents, like lithium aluminum...
4.7K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Reference method matters: DXA system differences influence agreement with 3D optical imaging body composition estimates.

International journal of obesity (2005)·2026
Same author

Does Metabolically Healthy Obesity Really Exist: Going Toward New Definitions.

The Journal of clinical endocrinology and metabolism·2026
Same author

Within- and between-day reliability of laboratory-based body composition assessment methods.

The British journal of nutrition·2026
Same author

Comment on: Assessment of body composition following bariatric surgery using deuterium oxide derived method in adults with morbid obesity.

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery·2026
Same author

Resuscitation Quality Improvement Program for CPR Training and Cardiac Arrest Survival in Hospitals.

JAMA cardiology·2026
Same author

Self-administration of oral voluntary assisted dying medication in Victoria, Australia: the first 6 years.

BMJ supportive & palliative care·2026

相关实验视频

Updated: Feb 19, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

基于5-阿赞醇核心的NRAS G12D抑制剂的结构导向开发.

Joshua B Cox1, Vinay Nair1, Pijus Mandal1

  • 1Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States.

ACS medicinal chemistry letters
|February 18, 2026
PubMed
概括

研究人员开发了IACS-56676,这是针对黑色素瘤等癌症中发现的NRAS G12D突变的向治疗. 这种选择性抑制剂为研究NRAS生物学和癌症治疗提供了新的工具.

关键词:
在G12D突变中,G12D突变者这是一种KRAS抑制剂.它们是NRAS和NRAS.这就是SBDDSBDD的意思.精准医学是一门精准医学.基于结构的药物设计.有针对性的治疗.

更多相关视频

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.4K
Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase
11:01

Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase

Published on: November 23, 2016

10.3K

相关实验视频

Last Updated: Feb 19, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.4K
Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase
11:01

Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase

Published on: November 23, 2016

10.3K

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 药物发现 药物发现 药物发现

背景情况:

  • NRAS G12D突变驱动黑色素瘤和血液恶性瘤.
  • 目前,针对NRAS G12D的向治疗方法有限,这代表着未得到满足的临床需求.

研究的目的:

  • 描述一个新型NRAS G12D抑制剂IACS-56676的结构导向发展.
  • 建立IACS-56676作为NRAS生物学研究的工具化合物.
  • 为了了解NRAS和KRAS蛋白之间的选择性.

主要方法:

  • 使用结构导向药物设计原则.
  • 化合物的代优化,以提高功效和选择性.
  • 生物化学测试以评估对NRAS和KRAS变异的抑制剂活性.

主要成果:

  • IACS-56676被确定为NRAS G12D的选择性和强大的抑制剂.
  • 关键的结构修改,包括p-循环稳定和Leu 95替代,对于活动至关重要.
  • 该抑制剂对野生类型的KRAS和非响应型变体表现出选择性.

结论:

  • IACS-56676代表了针对NRAS G12D突变的重大进展.
  • 该化合物作为进一步调查NRAS驱动的瘤发生的一个有价值的工具.
  • 这项研究为开发选择性RAS抑制剂提供了一个框架.